An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's ...

Several companies on Wall Street have seen recent Seeking Alpha analyst activity, including both upgrades and downgrades. Gary Alexander has upgraded lululemon athletica (LULU) from Sell to Neutral, ...

Inquiry Into Regeneron Pharmaceuticals's Competitor Dynamics In Biotechnology Industry October 09, 2024 — 11:00 am EDT Written by Benzinga Insights for Benzinga -> ...

Shares of Regeneron Pharmaceuticals Inc. REGN slid 1.35% to $564.64 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.07% to ...

Going up against a giant. Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset.

Regeneron's Dupixent, developed with Sanofi (SNY), is currently approved for treating eczema in children as young as six. It's also on its way to being a drug worth $10 billion.

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.